These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer. Dunn C, Keam SJ. Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574 [Abstract] [Full Text] [Related]
3. Letrozole : in postmenopausal hormone-responsive early-stage breast cancer. Scott LJ, Keam SJ. Drugs; 2006; 66(3):353-62. PubMed ID: 16526826 [Abstract] [Full Text] [Related]
4. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893 [Abstract] [Full Text] [Related]
5. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L. Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808 [Abstract] [Full Text] [Related]
6. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Wiseman LR, Adkins JC. Drugs Aging; 1998 Oct; 13(4):321-32. PubMed ID: 9805213 [Abstract] [Full Text] [Related]
7. Letrozole. A review of its use in postmenopausal women with advanced breast cancer. Lamb HM, Adkins JC. Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997 [Abstract] [Full Text] [Related]
8. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. N Engl J Med; 2003 Nov 06; 349(19):1793-802. PubMed ID: 14551341 [Abstract] [Full Text] [Related]
9. Anti-tumor effects of letrozole. Miller WR, Anderson TJ, Dixon JM. Cancer Invest; 2002 Nov 06; 20 Suppl 2():15-21. PubMed ID: 12442345 [Abstract] [Full Text] [Related]
10. Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Dranitsaris G, Verma S, Trudeau M. Am J Clin Oncol; 2003 Jun 06; 26(3):289-96. PubMed ID: 12796603 [Abstract] [Full Text] [Related]
11. Role of anti-aromatase agents in postmenopausal advanced breast cancer. Murray R. Cancer Chemother Pharmacol; 2001 Oct 06; 48(4):259-65. PubMed ID: 11710624 [Abstract] [Full Text] [Related]
12. Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer. Keating GM. Drugs; 2009 Aug 20; 69(12):1681-705. PubMed ID: 19678717 [Abstract] [Full Text] [Related]
15. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M. Clin Ther; 2007 Aug 20; 29(8):1535-47. PubMed ID: 17919537 [Abstract] [Full Text] [Related]
18. Aromatase inhibitors in advanced breast cancer. Mouridsen HT. Semin Oncol; 2004 Dec 20; 31(6 Suppl 12):3-8. PubMed ID: 15719595 [Abstract] [Full Text] [Related]
19. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA. Ann Oncol; 2005 May 20; 16(5):707-15. PubMed ID: 15817595 [Abstract] [Full Text] [Related]
20. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Clin Cancer Res; 2005 Aug 15; 11(16):5671-7. PubMed ID: 16115902 [Abstract] [Full Text] [Related] Page: [Next] [New Search]